FUBIMINA acts as a reasonably potent
agonist for the
CB2 receptor (
Ki = 23.45 nM), with 12x selectivity over
CB1 (Ki = 296.1 nM), and does not fully substitute for
Δ9-THC in rat discrimination studies.[4]
Related benzimidazole derivatives have been reported to be highly selective
agonists for the
CB2 receptor.[5]
^Uchiyama N, Shimokawa Y, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2014). "Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products". Forensic Toxicology. 32 (1): 105–115.
doi:
10.1007/s11419-013-0217-2.
S2CID32599561.
FUBIMINA acts as a reasonably potent
agonist for the
CB2 receptor (
Ki = 23.45 nM), with 12x selectivity over
CB1 (Ki = 296.1 nM), and does not fully substitute for
Δ9-THC in rat discrimination studies.[4]
Related benzimidazole derivatives have been reported to be highly selective
agonists for the
CB2 receptor.[5]
^Uchiyama N, Shimokawa Y, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2014). "Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products". Forensic Toxicology. 32 (1): 105–115.
doi:
10.1007/s11419-013-0217-2.
S2CID32599561.